Latest Developments in Global Nanomechanical Testing Market

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Global Nanomechanical Testing Market

  • Semiconductors and Electronics
  • May 2025
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

  • In October 2020, Bruker Nanomechanical Testing unveiled the Hysitron PI 89 SEM PicoIndenter, designed to offer nanomechanical testing within a scanning electron microscope (SEM). This new device enables testing at higher loads and in more demanding environments than before, enhancing researchers' ability to study the deformation mechanisms of high-strength materials
  • In October 2023, Bruker launched the Hysitron TI 990 TriboIndenter, a next-generation nanomechanical test system. This device offers faster testing throughput, an expanded testing area, and enhanced automation, making it ideal for applications like polymer research, alloy development, and semiconductor characterization. The TI 990 also features advanced feedback controls and dynamic nanoindentation capabilities, providing improved measurement flexibility and ease of operation. It is designed to meet the growing demands of various industries for precise mechanical testing at the nanoscale
  • ​In March 2022, Nanoacademic Technologies appointed 4AM Software Pty Ltd. as its exclusive distributor for Australia and New Zealand. This partnership aims to promote Nanoacademic's atomistic and quantum modeling software to researchers in materials science and advanced technology sectors, including quantum technologies
  • ​In October 2022, MD Anderson Cancer Center and ARTIDIS AG formed a strategic alliance to clinically validate ARTIDIS's nanomechanical technology for optimizing cancer treatment. The ARTIDIS atomic force microscopy platform rapidly assesses the physical properties of tumor tissues at the nanoscale, aiding in identifying biomarker signatures that guide personalized therapeutic strategies. This collaboration focuses on solid tumors, particularly in neoadjuvant chemotherapy and radiotherapy/immunotherapy applications, aiming to enhance treatment outcomes and integrate the technology into national cancer care standards